AVAX Technologies, Inc.

AVAX Technologies' M-Vax™ cancer vaccine extends five-year overall survival in patients with lymph node metastatic melanoma

The study confirms that M-Vax increases the survival rate of patients with advanced Stage III melanoma, even after disease recurrence. Patients who developed an immune response against their melanoma had a far better outcome, with a five-year survival rate of 65%.

SourceAVAX Technologies, Inc.·DateMay 22, 2000

AVAX Technologies' O-Vax™ cancer vaccine induces positive immunological and clinical outcomes in patients with advanced ovarian cancer

The data from an ongoing Phase 1/2 trial of O-Vax in patients with advanced ovarian cancer indicates that the vaccine induces a positive immunological response, as measured by a delayed type hypersensitivity test. Favorable clinical responses were also observed, including complete regression of tumors and normalization of CA-125 levels.

SourceAVAX Technologies, Inc.·DateMay 21, 2000